BRPI0917147A2 - composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto. - Google Patents
composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto.Info
- Publication number
- BRPI0917147A2 BRPI0917147A2 BRPI0917147A BRPI0917147A BRPI0917147A2 BR PI0917147 A2 BRPI0917147 A2 BR PI0917147A2 BR PI0917147 A BRPI0917147 A BR PI0917147A BR PI0917147 A BRPI0917147 A BR PI0917147A BR PI0917147 A2 BRPI0917147 A2 BR PI0917147A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- salt
- making
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 3
- 150000003839 salts Chemical class 0.000 title 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9285108P | 2008-08-29 | 2008-08-29 | |
US61/092851 | 2008-08-29 | ||
PCT/SE2009/050972 WO2010024769A1 (en) | 2008-08-29 | 2009-08-28 | New benzofurans suitable as precursors to compounds that are useful for imaging amyloid deposits |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0917147A2 true BRPI0917147A2 (pt) | 2015-11-17 |
BRPI0917147B1 BRPI0917147B1 (pt) | 2020-09-15 |
BRPI0917147B8 BRPI0917147B8 (pt) | 2021-05-25 |
Family
ID=41721733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0917147A BRPI0917147B8 (pt) | 2008-08-29 | 2009-08-28 | composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto |
Country Status (22)
Country | Link |
---|---|
US (3) | US8193363B2 (pt) |
EP (1) | EP2328891B1 (pt) |
JP (1) | JP5613669B2 (pt) |
KR (1) | KR101648848B1 (pt) |
CN (3) | CN104447710A (pt) |
AR (2) | AR073230A1 (pt) |
AU (1) | AU2009286176B2 (pt) |
BR (1) | BRPI0917147B8 (pt) |
CA (1) | CA2735497C (pt) |
CL (1) | CL2011000420A1 (pt) |
CO (1) | CO6341628A2 (pt) |
EA (1) | EA019093B1 (pt) |
EC (1) | ECSP11010850A (pt) |
ES (1) | ES2627769T3 (pt) |
IL (1) | IL211188A0 (pt) |
MX (1) | MX2011001918A (pt) |
NZ (1) | NZ591446A (pt) |
PE (1) | PE20110393A1 (pt) |
TW (1) | TW201014848A (pt) |
UY (1) | UY32076A (pt) |
WO (1) | WO2010024769A1 (pt) |
ZA (1) | ZA201102284B (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8193363B2 (en) | 2008-08-29 | 2012-06-05 | Astrazeneca Ab | Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits |
JP5825608B2 (ja) * | 2010-08-06 | 2015-12-02 | 国立大学法人京都大学 | ピリジルベンゾフラン誘導体 |
US10098859B2 (en) | 2012-09-05 | 2018-10-16 | Amri Ssci, Llc | Cocrystals of p-coumaric acid |
EP2767532B1 (en) | 2012-12-21 | 2016-07-13 | National Institutes for Quantum and Radiological Science and Technology | Novel compound for imaging tau protein accumulated in the brain |
WO2016029146A1 (en) * | 2014-08-22 | 2016-02-25 | University Of Washington | Specific inhibitors of methionyl-trna synthetase |
WO2017087965A1 (en) * | 2015-11-20 | 2017-05-26 | Navidea Biopharmaceuticals, Inc. | Formulations for 2-heteroaryl substituted benzofurans |
EP3790883A4 (en) | 2018-05-09 | 2022-08-24 | Aprinoia Therapeutics Limited | HETEROARYL COMPOUNDS AND USES THEREOF |
EP4058065A4 (en) | 2019-11-13 | 2023-05-03 | Aprinoia Therapeutics Limited | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND THEIR USES |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1041525A (en) | 1964-11-11 | 1966-09-07 | Belge Produits Chimiques Sa | Benzofuran derivatives and processes for preparing the same |
EP0735821A4 (en) | 1993-12-21 | 1998-04-01 | Lilly Co Eli | METHODS FOR TREATING OR PREVENTING CONDITIONS ASSOCIATED WITH AMYLO DOGEN PEPTIDES |
EP1224175B1 (en) * | 1999-10-15 | 2004-03-17 | F. Hoffmann-La Roche Ag | Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
FR2800069A1 (fr) * | 1999-10-22 | 2001-04-27 | Centre Nat Rech Scient | 3-amino-2,2-di-c-alkyl-1,4-butyrolactones et 1,4- thiobutyrolactones n-substituees utiles comme stimulant de l'activite de l'acide gamma-aminobutyrique et leur procede de preparation |
US20040077654A1 (en) | 2001-01-15 | 2004-04-22 | Bouillot Anne Marie Jeanne | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
JP4307001B2 (ja) | 2001-03-14 | 2009-08-05 | キヤノン株式会社 | 金属配位化合物、電界発光素子及び表示装置 |
GB0130305D0 (en) * | 2001-12-19 | 2002-02-06 | Amersham Plc | Compounds for imaging alzheimers disease |
DE60326735D1 (de) | 2002-08-02 | 2009-04-30 | Genesoft Pharmaceuticals Inc | Biaryl-verbindungen mit antiinfektiver wirkung |
EP1631561B1 (en) * | 2003-05-07 | 2010-08-18 | General Electric Company | Compositions and methods for non-invasive imaging of soluble beta-amyloid |
US20040223912A1 (en) * | 2003-05-07 | 2004-11-11 | Montalto Michael Christopher | Compositions and methods for non-invasive imaging of soluble beta-amyloid |
JP2007516196A (ja) | 2003-07-02 | 2007-06-21 | ガラパゴス エヌブイ | Rhoキナーゼ阻害剤としてのピラジン及びピラリジン誘導体 |
ZA200701232B (en) * | 2004-07-15 | 2008-08-27 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
EP2457901A1 (en) * | 2005-03-14 | 2012-05-30 | High Point Pharmaceuticals, LLC | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors |
US8501739B2 (en) | 2005-07-04 | 2013-08-06 | High Point Pharmaceuticals, Llc | Medicaments |
WO2007047204A1 (en) | 2005-10-11 | 2007-04-26 | University Of Pittsburgh | Isotopically-labeled benzofuran compounds as imagingagents foramyloidogenic proteins |
TW201018678A (en) * | 2006-01-27 | 2010-05-16 | Astrazeneca Ab | Novel heteroaryl substituted benzothiazoles |
EP2113258A1 (en) * | 2006-12-05 | 2009-11-04 | Nagasaki University | Aurone derivative-containing composition for diagnosis |
JP4328820B2 (ja) | 2007-01-10 | 2009-09-09 | 田辺三菱製薬株式会社 | 医薬組成物 |
TW200901998A (en) * | 2007-03-06 | 2009-01-16 | Astrazeneca Ab | Novel 2-heteroaryl substituted benzothiophenes and benzofuranes |
US8193363B2 (en) * | 2008-08-29 | 2012-06-05 | Astrazeneca Ab | Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits |
-
2009
- 2009-08-20 US US12/544,556 patent/US8193363B2/en active Active
- 2009-08-27 UY UY0001032076A patent/UY32076A/es not_active Application Discontinuation
- 2009-08-27 TW TW098128873A patent/TW201014848A/zh unknown
- 2009-08-28 AU AU2009286176A patent/AU2009286176B2/en active Active
- 2009-08-28 BR BRPI0917147A patent/BRPI0917147B8/pt active IP Right Grant
- 2009-08-28 CN CN201410655681.5A patent/CN104447710A/zh active Pending
- 2009-08-28 CN CN200980142788.7A patent/CN102197036B/zh active Active
- 2009-08-28 WO PCT/SE2009/050972 patent/WO2010024769A1/en active Application Filing
- 2009-08-28 EP EP09810319.5A patent/EP2328891B1/en active Active
- 2009-08-28 NZ NZ591446A patent/NZ591446A/xx not_active IP Right Cessation
- 2009-08-28 CN CN201410653507.7A patent/CN104478862B/zh active Active
- 2009-08-28 KR KR1020117004579A patent/KR101648848B1/ko active IP Right Grant
- 2009-08-28 PE PE2011000219A patent/PE20110393A1/es not_active Application Discontinuation
- 2009-08-28 EA EA201100267A patent/EA019093B1/ru not_active IP Right Cessation
- 2009-08-28 JP JP2011524942A patent/JP5613669B2/ja active Active
- 2009-08-28 ES ES09810319.5T patent/ES2627769T3/es active Active
- 2009-08-28 CA CA2735497A patent/CA2735497C/en active Active
- 2009-08-28 AR ARP090103323A patent/AR073230A1/es active IP Right Grant
- 2009-08-28 MX MX2011001918A patent/MX2011001918A/es active IP Right Grant
-
2011
- 2011-02-10 IL IL211188A patent/IL211188A0/en unknown
- 2011-02-21 CO CO11020875A patent/CO6341628A2/es not_active Application Discontinuation
- 2011-02-25 CL CL2011000420A patent/CL2011000420A1/es unknown
- 2011-02-28 EC EC2011010850A patent/ECSP11010850A/es unknown
- 2011-03-28 ZA ZA2011/02284A patent/ZA201102284B/en unknown
-
2012
- 2012-06-04 US US13/487,349 patent/US8653274B2/en active Active
-
2014
- 2014-01-07 US US14/149,563 patent/US9309267B2/en active Active
-
2018
- 2018-11-12 AR ARP180103297A patent/AR114029A2/es active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0918038A2 (pt) | Processos para preparar um composto e um sal, e, composto | |
BRPI0910734A2 (pt) | composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo. | |
BRPI0717751A2 (pt) | Processo para a fabricação de um composto, composto, e, sal de um composto. | |
BRPI0812054A2 (pt) | Processo para preparar compostos, e, compostos. | |
BRPI0908252A2 (pt) | Processo para preparar um composto, e, uso de um composto | |
BRPI0718155A2 (pt) | Composto, uso de um composto, método para tratar doenças mediadas por glk, e, processo para a preparação de um composto. | |
BRPI0916609A2 (pt) | Processo para a preparação de um macrociclo | |
BRPI0922475A2 (pt) | composto, composição farmacêutica , método para tratar câncer, e, uso de um composto. | |
BRPI0919018A2 (pt) | sal farmaceuticamente aceitável, uso de sal, e, processo para a preparação de sal | |
BRPI0810076A2 (pt) | Processo para preparar compostos, uso de compostos, composto, e mistura. | |
BRPI0816331A2 (pt) | Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto. | |
BRPI0911898A2 (pt) | processo para preparar compostos, e, composto. | |
BRPI0918850A2 (pt) | dispositivo para a substituição automática de catalisador, processo para a substituição automática de catalisador, e , uso de um dispositivo ou de um processo | |
BRPI0718386A2 (pt) | Processo para preparação de catalisadores. | |
BRPI0917147A2 (pt) | composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto. | |
BRPI0911897A2 (pt) | Processo para a preparação de compostos, e, composto | |
BRPI0911531A2 (pt) | processo para preparar iopromida, e, composto. | |
BRPI0813438A2 (pt) | Processo para preparar um composto, uso de um composto, e, composto. | |
BRPI0908738A2 (pt) | composto, medicamento, uso de um composto, e, processo para preparar os compostos | |
BRPI1014691A2 (pt) | Composto, e, processo para a preparação de um composto. | |
BRPI0817305A2 (pt) | Sal de amina orgânica, e, processo para produzir um sal de amina orgânica. | |
BRPI0820290A2 (pt) | Processo para preparar um sal de dibenzoil-l-tartarato diastereomericamente puro de um composto, mono-dibenzoil-l-tartarato, e, uso de um dibenzoil-l-tartarato. | |
BRPI0912163A2 (pt) | Composto químico, processo para a produção de um composto, compsição química, e, uso de um composto químico. | |
BRPI0817010A2 (pt) | Processo de preparação de um composto p-hidroximandélico eventualmente substituído e derivado e de um aldeído 4-hidroxiaromático. | |
BRPI0907987A2 (pt) | uso de malonatos de benzilideno, processo para a preparação de compostos, preparação cosmética, e compostos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/08/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |